Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R.

Clin Cancer Res. 2018 Apr 15;24(8):1785-1794. doi: 10.1158/1078-0432.CCR-17-1970. Epub 2017 Dec 6. Review.

PMID:
29212781
2.

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.

Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS.

Invest New Drugs. 2018 Jun;36(3):416-423. doi: 10.1007/s10637-017-0513-5. Epub 2017 Oct 19.

PMID:
29047029
3.

Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs.

Bugano DDG, Hess K, Jardim DLF, Zer A, Meric-Bernstam F, Siu LL, Razak ARA, Hong DS.

Clin Cancer Res. 2017 Aug 1;23(15):4020-4026. doi: 10.1158/1078-0432.CCR-16-2354. Epub 2017 Apr 4.

PMID:
28377482
4.

Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review.

Jardim DL, Groves ES, Breitfeld PP, Kurzrock R.

Cancer Treat Rev. 2017 Jan;52:12-21. doi: 10.1016/j.ctrv.2016.10.009. Epub 2016 Nov 4. Review.

PMID:
27883925
5.

An appraisal of drug development timelines in the Era of precision oncology.

Jardim DL, Schwaederle M, Hong DS, Kurzrock R.

Oncotarget. 2016 Aug 16;7(33):53037-53046. doi: 10.18632/oncotarget.10588.

6.

Response.

Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R.

J Natl Cancer Inst. 2016 Feb 24;108(3):djw001. doi: 10.1093/jnci/djw001. Print 2016 Mar. No abstract available.

PMID:
26912651
7.

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.

de Melo Gagliato D, Jardim DL, Marchesi MS, Hortobagyi GN.

Oncotarget. 2016 Sep 27;7(39):64431-64446. doi: 10.18632/oncotarget.7043. Review.

8.

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R.

J Natl Cancer Inst. 2015 Sep 15;107(11). pii: djv253. doi: 10.1093/jnci/djv253. Print 2015 Nov. Erratum in: J Natl Cancer Inst. 2016 Feb;108(2). pii: djv423. doi: 10.1093/jnci/djv423.

9.

Phase I trials of antitumour agents: fundamental concepts.

Toloi Dde A, Jardim DL, Hoff PM, Riechelmann RS.

Ecancermedicalscience. 2015 Jan 19;9:501. doi: 10.3332/ecancer.2015.501. eCollection 2015. Review.

10.

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors.

Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS.

Oncoscience. 2013 Dec 11;1(1):5-13. eCollection 2014.

11.

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.

Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS.

Clin Cancer Res. 2014 Dec 15;20(24):6336-45. doi: 10.1158/1078-0432.CCR-14-1293. Epub 2014 Oct 17.

12.

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.

Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS.

Clin Cancer Res. 2014 Dec 1;20(23):5956-63. doi: 10.1158/1078-0432.CCR-14-1582. Epub 2014 Oct 14.

13.

Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.

Donnard E, Asprino PF, Correa BR, Bettoni F, Koyama FC, Navarro FC, Perez RO, Mariadason J, Sieber OM, Strausberg RL, Simpson AJ, Jardim DL, Reis LF, Parmigiani RB, Galante PA, Camargo AA.

Oncotarget. 2014 Oct 15;5(19):9199-213.

14.

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.

Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS.

Clin Genitourin Cancer. 2015 Feb;13(1):e19-26. doi: 10.1016/j.clgc.2014.06.017. Epub 2014 Jul 3.

15.

Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.

de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS.

Clin Breast Cancer. 2014 Dec;14(6):468-74. doi: 10.1016/j.clbc.2014.06.001. Epub 2014 Jun 23.

16.

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.

Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS.

Oncotarget. 2014 Apr 15;5(7):1837-45.

17.

MET in ovarian cancer: metastasis and resistance?

Tang C, Jardim DL, Hong D.

Cell Cycle. 2014;13(8):1220-1. doi: 10.4161/cc.28515. Epub 2014 Mar 12. No abstract available.

18.

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.

Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS.

PLoS One. 2014 Feb 19;9(2):e89388. doi: 10.1371/journal.pone.0089388. eCollection 2014.

19.

Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs.

Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS.

Clin Cancer Res. 2014 Jan 15;20(2):281-8. doi: 10.1158/1078-0432.CCR-13-2103. Epub 2013 Nov 4.

20.
21.

Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience.

Jardim DL, Gagliato Dde M, Ribeiro KB, Shimada AK, Katz A.

Drugs R D. 2012 Dec 1;12(4):207-16. doi: 10.2165/11636760-000000000-00000.

22.

Oxaliplatin-related thrombocytopenia.

Jardim DL, Rodrigues CA, Novis YA, Rocha VG, Hoff PM.

Ann Oncol. 2012 Aug;23(8):1937-42. doi: 10.1093/annonc/mds074. Epub 2012 Apr 25. Review.

PMID:
22534771
23.

Autoimmune features caused by dengue fever: a case report.

Jardim DL, Tsukumo DM, Angerami RN, Carvalho Filho MA, Saad MJ.

Braz J Infect Dis. 2012 Jan-Feb;16(1):92-5.

24.

Haematologic toxicities associated with the addition of bevacizumab in cancer patients.

Schutz FA, Jardim DL, Je Y, Choueiri TK.

Eur J Cancer. 2011 May;47(8):1161-74. doi: 10.1016/j.ejca.2011.03.005. Epub 2011 Apr 4.

PMID:
21470847
25.

Social isolation and expression of serotonergic neurotransmission-related genes in several brain areas of male mice.

Bibancos T, Jardim DL, Aneas I, Chiavegatto S.

Genes Brain Behav. 2007 Aug;6(6):529-39. Epub 2006 Nov 3.

26.

Expression of Sara2 human gene in erythroid progenitors.

Jardim DL, da Cunha AF, Duarte Ada S, dos Santos CO, Saad ST, Costa FF.

J Biochem Mol Biol. 2005 May 31;38(3):328-33.

PMID:
15943909

Supplemental Content

Loading ...
Support Center